Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dyax has reported the issuance of a US patent covering the composition of matter for its lead product candidate DX-88, a recombinant small protein discovered from its proprietary phage display technology, to which it owns the worldwide rights.
Subscribe to our email newsletter
The recently issued patent will expire in 2023. Dyax now has a total of nine issued US patents covering DX-88 as well as other related kallikrein inhibitors and their uses.
The composition of matter patent strengthens Dyax’s intellectual property portfolio relating to its product candidate, DX-88, a highly specific and potent inhibitor of plasma kallikrein which is a key component in the regulation of inflammatory and blood clotting processes and thought to play a role in a number of inflammatory and autoimmune conditions. DX-88 is currently in a second Phase III trial, known as EDEMA4, for the treatment of acute attacks of hereditary angioedema (HAE) and a Phase II trial for reducing blood loss in on-pump cardiothoracic surgery (CTS).
Ivana Magovcevic-Liebisch, general counsel and executive vice president of administration at Dyax, said: “We view our patent portfolio as an important and valuable asset and, therefore, will continue to execute a strategy that builds our intellectual property base. The receipt of this most recent patent, in particular, demonstrates our commitment to this strategy, especially in relation to our late stage drug candidate DX-88.”